Effect of rapamycin combined with cisplatin on head and neck squamous cancer cells regulated by CCL19.
- Author:
Fa-yu LIU
1
;
Zhen-jin ZHAO
;
Peng LI
;
Xue DING
;
Chang-fu SUN
Author Information
- Publication Type:Journal Article
- MeSH: Antibiotics, Antineoplastic; administration & dosage; pharmacology; Antineoplastic Agents; administration & dosage; pharmacology; Apoptosis; drug effects; Carcinoma, Squamous Cell; pathology; Cell Cycle; drug effects; Cell Line, Tumor; Cell Proliferation; drug effects; Chemokine CCL19; antagonists & inhibitors; pharmacology; Cisplatin; administration & dosage; pharmacology; Drug Synergism; Head and Neck Neoplasms; pathology; Humans; Sirolimus; administration & dosage; pharmacology
- From: Chinese Journal of Stomatology 2011;46(4):197-200
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the synergistic effects of rapamycin and cisplatin on head and neck squamous cancer cells regulated by chemokine (C-C motif) ligand 19 (CCL19).
METHODSThe role of rapamycin and cisplatin was detected on cell-cycle and apoptosis in CCL19 induced PCI-4B and PCI-37B cells by methyl thiazolyl tetrazolium (MTT) and flow cytometry (FCM). Dose-effect relationship parameters and combination index (CI) were calculated on the median-effect equation and multiple drug effect equation using computer software CalcuSyn. Statistical analysis was performed by the unpaired student's t-test.
RESULTSRapamycin and cisplatin could respectively increase the growth arrest, the proportion of G(1) phase and apoptosis of CCL19 induced cancer cells (P < 0.05). Under inhibitory concentration 50% (IC(50)), CI was less than 1, and in IC(75), it was more than 1 in PCI-4B cells. In PCI-37B cells, under IC(75), CI was less than 1, and in IC(90), it was more than 1.
CONCLUSIONSRapamycin and cisplatin can inhibit CCL19-regulated PCI-4B and PCI-37B cells' survival. The two drugs have synergistic effects when used in combination.
